Is it appropriate to compare the results from two clinical trials with one drug in common?
Grupo de Investigación en Genética y Epidemiología Cardiovascular, Programa de Investigación en Procesos Inflamatorios y Cardiovasculares, IMIM-Hospital del Mar, Barcelona, Spain.
Jaume
J
Marrugat
Grupo de Investigación en Genética y Epidemiología Cardiovascular, Programa de Investigación en Procesos Inflamatorios y Cardiovasculares, IMIM-Hospital del Mar, Barcelona, Spain.
Joan
J
Vila
Grupo de Investigación en Genética y Epidemiología Cardiovascular, Programa de Investigación en Procesos Inflamatorios y Cardiovasculares, IMIM-Hospital del Mar, Barcelona, Spain. Electronic address: relosua@imim.es.
Roberto
R
Elosua
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000241:Adenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D000077144:Clopidogrel; D005260:Female; D006801:Humans; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013876:Thiophenes / Q000627:therapeutic use*; D000077486:Ticagrelor; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D013876:Thiophenes; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine; D013988:Ticlopidine